PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jurbhealthspringer.comThis journalToc AlertsSubmit OnlineOpen ChoiceThis journal
 
J Urban Health. 2005 September; 82(3): 411–419.
PMCID: PMC3456063

Attitudes and practices regarding the use of methadone in US State and federal prisons

Abstract

In the United States, vigorous enforcement of drug laws and stricter sentencing guidelines over the past 20 years have contributed to an expanded incarcerted population with a high rate of drug use. One in five state prisoners reports a history of injection drug use, and many are opiate dependent. For over 35 years, methadone maintenance therapy has been an effective treatment for opiate dependence; however, its use among opiate-dependent inmates in the United States is limited. In June 2003, we conducted a survey of the medical directors of all 50 US states and the federal prison system to describe their attitudes and practices regarding methadone. Of the 40 respondents, having jurisdiction over 88% (n=1,266,759) of US prisoners, 48% use methadone, predominately for pregnant inmates or for short-term detoxification. Only 8% of respondents refer opiate-dependent inmates to methadone programs upon release. The results highlight the need to destigmatize the use of methadone in the incarcerated setting, expand access to methadone during incarceration, and to improve linkage to methadone treatment for opiate-dependent offenders who return to the community.

Full Text

The Full Text of this article is available as a PDF (88K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Bureau of Justice Statistics. Corrections statistics: summary findings. Available at: http:// www.ojp.usdoj.gov/bjs/correct.htm. Accessed May 4, 2005.
2. Federal Bureau of Investigation. Uniform crime reports: crime in the United States. Available at: http://www.fbi.gov/ucr/ucr.htm. Accessed May 4, 2005.
3. Drucker E. Drug prohibition and public health: 25 years of evidence. Public Health Rep. 1999;114:14–29. doi: 10.1093/phr/114.1.14. [PMC free article] [PubMed] [Cross Ref]
4. Center for Disease Control and Prevention. Drug use, HIV, and the criminal justice system. IDU HIV Prevention, 2001. Available at: http://www.cdc.gov/idu/facts/criminaljusticefactsheet. pdf. Accessed May 4, 2005.
5. Califano JA. Behind Bars: Substance Abuse and America’s Prison Population. Population, CASA Report. New York, New York: National Center on Addiction and Substance Abuse at Columbia University; 1998.
6. Bureau of Justice Statistics. Substance abuse and treatment of state and federal prisoners, 1999. Available at: http://www.ojp.usdoj.gov/bjs/abstract/satsfp97.htm. Accessed May 4, 2005.
7. Hammett TD, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releases from US correctional facilities. Am J Public Health. 2002;92:1789–1794. [PubMed]
8. Spaulding A, Greene C, Davidson K, Schneidermann M, Rich JD. Hepatitis C in state correctional facilities. Prev Med. 1999;28:92–100. doi: 10.1006/pmed.1998.0418. [PubMed] [Cross Ref]
9. Reindollar RW. Hepatitis C and the correctional population. Am J Med. 1999;107:100S–103S. doi: 10.1016/S0002-9343(99)00394-0. [PubMed] [Cross Ref]
10. Centers for Disease Control and Prevention (CDC) Prevention and control of infections with hepatitis viruses in correctional settings. MM WR Morb Mortal Wkly Rep. 2003;52:1–36.
11. Rapposelli KK, Kennedy MG, Miles JR, et al. HIV/AIDS in correctional settings: a salient priority for the CDC and HRSA. AIDS Educ Prev. 2002;14:103–113. doi: 10.1521/aeap.14.7.103.23861. [PubMed] [Cross Ref]
12. Nurco DN, Hanlon TE, Kinlock TW. Recent research on the relationship between illicit drug use and crime. Behav Sci Law. 1991;9:221–242.
13. Nurco DN, Stephenson PE, Hanlon TE. Affercare/relapse prevention and the self-help movement. Addiction. 1991;25:1179–1200.
14. Hanlon TE, Nurco DN, Kinlock TW, Duszynski KR. Trends in criminal activity and drug use over an addiction career. Am J Drug Alcohol Abuse. 1990;16:223–238. [PubMed]
15. Inciardi JA, McBride D, Suratt H. The heroin street addict: profiling a national population. In: Inciardi JA, Harrison LD, editors. Heroin in the Age of Crack-Cocaine. Thousand Oaks, CA: Sage; 1998. pp. 31–50.
16. Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ. 1998;316:426–428. [PMC free article] [PubMed]
17. Bird SM, Hutchinson SJ. Male drug-related deaths in the fortnight after release from prison: Scotland. Addiction. 2003;98:185–190. doi: 10.1046/j.1360-0443.2003.00264.x. [PubMed] [Cross Ref]
18. Singleton N, Taylor C, Farrell M, Marsden J. Drug-Related Mortality Among Newly Released Offenders. London: Communications Development Unit, Home Office; 2003.
19. Weatherburn D, Lind B. Heroin harm minimisation: do we really have to choose between law enforcement and treatment? Crime Justice Bull. 1999;46:1–11.
20. Seal KH, Kral AH, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area. Am J Public Health. 2001;91:1842–1846. [PubMed]
21. Merrill J, Alterman A, Cacciola J, Rutherford M. Prior treatment history and its impact on criminal recidivism. J Subst Abuse Treat. 1999;17:313–319. doi: 10.1016/S0740-5472(99)00012-4. [PubMed] [Cross Ref]
22. Dole V, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med. 1969;280:1372–1375. doi: 10.1056/NEJM196906192802502. [PubMed] [Cross Ref]
23. McGlothlin WH, Anglin MD, Wilson BD. Outcome of the California civil addict commitments. Drug Alcohol Depend. 1976;1:165–181. doi: 10.1016/0376-8716(76)90027-2. [PubMed] [Cross Ref]
24. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953–1959. doi: 10.1001/jama.269.15.1953. [PubMed] [Cross Ref]
25. Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med. 2001;68:62–74. [PubMed]
26. Sees K, Delucci K, Masson C, et al. Methadone maintenance vs. 180-day psychologically enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283:1303–1310. doi: 10.1001/jama.283.10.1303. [PubMed] [Cross Ref]
27. Nestler EJ, Aghanajanian GK. Molecular and cellular basis of addiction. Science. 1997;278:58–63. doi: 10.1126/science.278.5335.58. [PubMed] [Cross Ref]
28. Ward J, Mattick RP, Hall W, editors. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Australia: Harwood Academic Publishers; 1998.
29. Metzger D, Navaline H, Woody G. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;133:97–106. [PMC free article] [PubMed]
30. Capelhom JRM, Ross MW. Methadone maintenance and the likelihood of risky needlesharing. Addiction. 1995;30:685–698.
31. Newman RG, Bashkow S, Cates M. Arrest histories before and after admission to methadone. Contemp Drug Probl.1973:417–430.
32. Center for Disease Control and Prevention. Substance abuse treatment for drug users in the cirminal justice system. IDU HIV Prevention, 2002. Available at: http:// www.cdc.gov/idu/facts/TreatmentFin.pdf. Accessed May 4, 2005.
33. Martin SS, Butzin CA, Saum CA, Inciardi JA. Three-year outcomes of therapeutic community treatment for drug-involved offenders in Delaware: from prison to work release to aftercare. Prison J. 1999;79:294–320. doi: 10.1177/0032885599079003002. [Cross Ref]
34. Center for Disease Control and Prevention. Helping inmates return to the community. IDU HIV prevention, 2001. Available at: http://www.cdc.gov/idu/facts/cj-transition.pdf. Accessed May 4, 2005.
35. Grinstead O, Zack B, Faigeles B. Reducing post release risk behavior among HIV seropositive inmates: the health promotion program. AIDS Educ Prev. 2001;13:109–119. doi: 10.1521/aeap.13.2.109.19737. [PubMed] [Cross Ref]
36. Travis J, Solomon AL, Waul M. From prison to home: the dimensions and consequences of prison reentry. Urban Health Institute, 2001. Available at: http://www.urban.org/ pdfs/from_prison_to_home.pdf. Accessed May 4, 2005.
37. Dolan K, Wodak A. An international review of methadone provision in prisons. Addict Res. 1996;4:85–97.
38. Sibbald B. Methadone maintenance expands inside federal prisons. CMAJ. 2002;167:1154–1154. [PMC free article] [PubMed]
39. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003;72:59–65. doi: 10.1016/S0376-8716(03)00187-X. [PubMed] [Cross Ref]
40. Fallon BM. The Key Extended Entry Program (KEEP): from the community side of the bridge. Mt Sinai J Med. 2001;68:21–27. [PubMed]
41. Tomasino V, Swanson AJ, Nolan J, Shuman HI. The Key Extended Entry Program (KEEP): a metha done treatment program for opiate-dependent inmates. Mt Sinai J Med. 2001;68:14–20. [PubMed]
42. Gerra G, Ferri M, Polidori E, Santoro G, Zaimovic A, Sternieri E. Long-term methadone maintenance effectiveness: psychosocial and pharmacological variables. J Subst Abuse Treat. 2003;25:1–8. doi: 10.1016/S0740-5472(03)00031-X. [PubMed] [Cross Ref]
43. Consultation Document on Methadone/LAAM. Washington, DC: ONDCP; 1998.
44. Warren E, Viney R. CHERE: an economic evaluation of the prison methadone program in New South Wales, 2004: Available at: http://www.chere.uts.edu.au/pdf/rep22.pdf. Accessed May 4, 2005.
45. Clarke JG, Stein MD, Hanna L, Sobota M, Rich JD. Active and former IDU report of HIV risk behaviors during periods of incarceration. Subst Abuse. 2001;22:209–216. doi: 10.1023/A:1012213827321. [Cross Ref]
46. Calzavara LM, Burchell AN, Schlossberg J, et al. Prior opiate injection and incarceration history predict injection drug use among inmates. Addiction. 2003;98:1257–1265. doi: 10.1046/j.1360-0443.2003.00466.x. [PubMed] [Cross Ref]
47. Koulierakis G, Gnardellis C, Agrafiotis D, Power KG. HIV risk behaviour correlates among injecting drug users in Greek prisons. Addiction. 2000;95:1207–1216. doi: 10.1046/j.1360-0443.2000.95812077.x. [PubMed] [Cross Ref]
48. Champion JK, Taylor A, Hutchinson S, et al. Incidence of hepatitis C virus infection and associated risk factors among Scottish prison inmates: a cohort study. Am J Epidemiol. 2004;159:514–519. doi: 10.1093/aje/kwh061. [PubMed] [Cross Ref]
49. Macalino GE, Vlahov D, Sandford S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;4:1218–1223. doi: 10.2105/AJPH.94.7.1218. [PubMed] [Cross Ref]
50. Magura S, Rosenblum A, Joseph H. Evaluation of in-jail methadone maintenance: preliminary results. NIDA Research Monograph. 1992;118:192–210. [PubMed]
51. Rich JD, McKenzie M, Carleton JC, Rizzi MA, Wolf FA, Crosland C. Linkage to methadone upon release from incarceration: a model. Paper presented at: APHA 131 st Annual Meeting; November 19, 2003; San Francisco.
52. United States Code of Federal Regulations Certification of Opioid Treatment Programs, 42 CFR §8, 2005. Available at: http://dpt.samhsa.gov/otp.htm. Accessed May 4, 2005.

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine